Andrew Galligan
Director
diaDexus, Inc. Committee Membership: Chair, Audit Committee
Andrew Galligan joined the diaDexus Board of Directors in November, 2010 and chairs the Audit Committee. He is currently Vice President of Finance and Chief Financial Officer of Nevro Corp, a Menlo Park, California-based medical device company with a CE-approved implantable spinal cord stimulation device being commercialized in Europe.
Prior to joining Nevro, Andrew held the same position at OOMA, a consumer electronics manufacturer and VOIP service provider, and before that, Andrew was VP Finance and CFO of Reliant Technologies, a pioneer of fractional resurfacing skin treatments with aesthetic lasers. He has also held the top financial executive position with Metrika, Corcept Therapeutics, Amira Medical, Molecular Devices and several other medical device companies. Andrew began his career at KPMG. He brings to the diaDexus Board many years of experience in financing the commercialization of innovative device and diagnostic technologies, both in the public and private arena.
Andrew received his degree in Business Studies from Trinity College, Dublin, Ireland. He is a Fellow of the Institute of Chartered Accountants in Ireland.